These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16246120)

  • 21. LPA receptor signaling: pharmacology, physiology, and pathophysiology.
    Yung YC; Stoddard NC; Chun J
    J Lipid Res; 2014 Jul; 55(7):1192-214. PubMed ID: 24643338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bilayer-Mediated Structural Transitions Control Mechanosensitivity of the TREK-2 K2P Channel.
    Aryal P; Jarerattanachat V; Clausen MV; Schewe M; McClenaghan C; Argent L; Conrad LJ; Dong YY; Pike ACW; Carpenter EP; Baukrowitz T; Sansom MSP; Tucker SJ
    Structure; 2017 May; 25(5):708-718.e2. PubMed ID: 28392258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells.
    Zhao Y; Usatyuk PV; Cummings R; Saatian B; He D; Watkins T; Morris A; Spannhake EW; Brindley DN; Natarajan V
    Biochem J; 2005 Jan; 385(Pt 2):493-502. PubMed ID: 15461590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.
    Lin ME; Herr DR; Chun J
    Prostaglandins Other Lipid Mediat; 2010 Apr; 91(3-4):130-8. PubMed ID: 20331961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators.
    Nishimasu H; Okudaira S; Hama K; Mihara E; Dohmae N; Inoue A; Ishitani R; Takagi J; Aoki J; Nureki O
    Nat Struct Mol Biol; 2011 Feb; 18(2):205-12. PubMed ID: 21240269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.
    Yang F; Chen GX
    World J Gastroenterol; 2018 Sep; 24(36):4132-4151. PubMed ID: 30271079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
    Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LPA modulates monocyte migration directly and via LPA-stimulated endothelial cells.
    Gustin C; Van Steenbrugge M; Raes M
    Am J Physiol Cell Physiol; 2008 Oct; 295(4):C905-14. PubMed ID: 18632732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?
    Balijepalli P; Sitton CC; Meier KE
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
    Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
    Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TREK-2, a new member of the mechanosensitive tandem-pore K+ channel family.
    Bang H; Kim Y; Kim D
    J Biol Chem; 2000 Jun; 275(23):17412-9. PubMed ID: 10747911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysophosphatidic acid receptors in cancer pathobiology.
    Tsujiuchi T; Araki M; Hirane M; Dong Y; Fukushima N
    Histol Histopathol; 2014 Mar; 29(3):313-21. PubMed ID: 24194373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs.
    Liliom K; Tsukahara T; Tsukahara R; Zelman-Femiak M; Swiezewska E; Tigyi G
    Biochim Biophys Acta; 2006 Dec; 1761(12):1506-14. PubMed ID: 17092771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diverse effects of LPA receptors on cell motile activities of cancer cells.
    Tsujiuchi T; Hirane M; Dong Y; Fukushima N
    J Recept Signal Transduct Res; 2014 Jun; 34(3):149-53. PubMed ID: 24460191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysophosphatidic acid reduces the organ injury caused by endotoxemia-a role for G-protein-coupled receptors and peroxisome proliferator-activated receptor-gamma.
    Murch O; Collin M; Thiemermann C
    Shock; 2007 Jan; 27(1):48-54. PubMed ID: 17172980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysophospholipids open the two-pore domain mechano-gated K(+) channels TREK-1 and TRAAK.
    Maingret F; Patel AJ; Lesage F; Lazdunski M; Honoré E
    J Biol Chem; 2000 Apr; 275(14):10128-33. PubMed ID: 10744694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.
    McIntyre TM; Pontsler AV; Silva AR; St Hilaire A; Xu Y; Hinshaw JC; Zimmerman GA; Hama K; Aoki J; Arai H; Prestwich GD
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):131-6. PubMed ID: 12502787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors.
    Valentine WJ; Fells JI; Perygin DH; Mujahid S; Yokoyama K; Fujiwara Y; Tsukahara R; Van Brocklyn JR; Parrill AL; Tigyi G
    J Biol Chem; 2008 May; 283(18):12175-87. PubMed ID: 18316373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.